Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis
JG Krueger, IB Walters, M Miyazawa… - Journal of the American …, 2000 - Elsevier
Background: Daclizumab is a humanized antibody to the α-subunit (CD25) of the interleukin
2 (IL-2) receptor that blocks normal IL-2 binding to this receptor. Because IL-2 is a major
stimulus for T-cell growth, blockade of the IL-2 receptor could be useful in treating T-cell-
mediated (autoimmune) diseases. Objective: Our purpose was to determine whether
adequate concentrations of antibody were achieved in circulating blood and in psoriatic skin
lesions to saturate CD25 receptors. We also intended to measure clinical effect and safety of …
2 (IL-2) receptor that blocks normal IL-2 binding to this receptor. Because IL-2 is a major
stimulus for T-cell growth, blockade of the IL-2 receptor could be useful in treating T-cell-
mediated (autoimmune) diseases. Objective: Our purpose was to determine whether
adequate concentrations of antibody were achieved in circulating blood and in psoriatic skin
lesions to saturate CD25 receptors. We also intended to measure clinical effect and safety of …